Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05134519
What this trial is testing

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Xijing Hospital 20
Post-approval studies (Phase 4)Not Yet RecruitingNCT07093931
What this trial is testing

Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Shandong Cancer Hospital and Institute 468
Testing effectiveness (Phase 2)Active Not RecruitingNCT06172127
What this trial is testing

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
MedSIR 165
Large-scale testing (Phase 3)UnknownNCT03500380
What this trial is testing

RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Who this might be right for
Breast NeoplasmsBreast DiseasesCapecitabine+3 more
RemeGen Co., Ltd. 301
Testing effectiveness (Phase 2)WithdrawnNCT05371860
What this trial is testing

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Armando Giuliano
Not applicableLooking for participantsNCT07358182
What this trial is testing

Efficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer

Who this might be right for
Trastuzumab-rezetecanHER2-low Breast CancerHER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Testing effectiveness (Phase 2)Ended earlyNCT05583110
What this trial is testing

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
Spanish Breast Cancer Research Group 13
Testing effectiveness (Phase 2)Study completedNCT01973660
What this trial is testing

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 151
Testing effectiveness (Phase 2)Study completedNCT01904903
What this trial is testing

Cardiac Safety Study in Patients With HER2 + Breast Cancer

Who this might be right for
HER2 Positive Breast CancerLeft Ventricular Function Systolic Dysfunction
Medstar Health Research Institute 31
Testing effectiveness (Phase 2)Study completedNCT01432223
What this trial is testing

Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

Who this might be right for
Breast CancerHER-2 Positive Breast CancerEffects of Chemotherapy
Osaka Medical College 46
Testing effectiveness (Phase 2)Ended earlyNCT01729884
What this trial is testing

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
University of Washington 3
Not applicableLooking for participantsNCT06693024
What this trial is testing

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 2,806
Testing effectiveness (Phase 2)Study completedNCT01340430
What this trial is testing

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

Who this might be right for
HER-2 Positive Breast Cancer
Lucia Del Mastro,MD 43
Not applicableStudy completedNCT07778407
What this trial is testing

TDXD in Metastatic HER2-Positive Breast Cancer

Who this might be right for
Breast Advanced Malignancies
Mansoura University 25
Testing effectiveness (Phase 2)Study completedNCT02910219
What this trial is testing

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients

Who this might be right for
Breast Cancer
Sandra Swain 53
Not applicableNot Yet RecruitingNCT07589972
What this trial is testing

Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer

Who this might be right for
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 45
Large-scale testing (Phase 3)Study completedNCT00005970
What this trial is testing

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Who this might be right for
Breast AdenocarcinomaHER2 Positive Breast CarcinomaStage IA Breast Cancer AJCC v7+4 more
National Cancer Institute (NCI) 3,436
Large-scale testing (Phase 3)Study completedNCT04957212
What this trial is testing

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Cinnagen 214
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Testing effectiveness (Phase 2)Active Not RecruitingNCT02849496
What this trial is testing

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable Breast Carcinoma+1 more
National Cancer Institute (NCI) 89
Next Page